SYNGENE Q1 FY24 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹808 Cr
verified against source
Revenue YoY
25%
reported change
EBITDA
₹212 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Syngene delivered a strong Q1 FY24 with INR 808 crore revenue (+25% YoY) and INR 212 crore EBITDA (+23% YoY), driven primarily by robust development and manufacturing services, particularly biologics manufacturing fulfilling the Zoetis contract. The constant currency revenue growth of 19% aligns with full-year guidance of high-teen growth. EBITDA margin contracted by 42 bps YoY to ~26.2%, impacted by forex losses of INR 15.5 crore (hedge rate INR 80.3 vs spot INR 87.2) and higher material costs from the shift toward manufacturing services. Strategic highlights include FDA approval for the Mangalore API facility (removing a key barrier for small molecule CDMO) and the INR 702 crore Stelis acquisition adding 20,000 liters of biologics capacity, effectively accelerating the capacity expansion roadmap by three years. PAT grew 26% to INR 93 crore with effective tax rate rising to ~22%. Management affirmed full-year guidance with expected CapEx reduction to $85 million from prior $100 million guidance due to the Stelis deal replacing internal biologics expansion. Key risks include near-term margin dilution from Stelis ramp-up before FY27 contribution, and normalization of research services growth from pandemic-era highs.
Colored figures show movement against the previous available record.
Guidance to track
- Management maintained full-year guidance despite expecting a shift in revenue mix toward development and manufacturing services. Constant currency growth of 19% in Q1 tracks in line with this target.
- Expected to remain around 30% if revenues are recognized at average hedge rate of ~INR 81/USD. Higher realized hedge rates could equate to lower margins due to hedge losses in P&L.
- Due to Stelis acquisition replacing internal biologics expansion CapEx, overall CapEx guidance for the year lowered. Initial guidance was $100 million with net capital guidance of $15 million.
- The 20,000L biologics facility expected to reach positive contribution to bottom line from FY2027, with 1x asset turnover achievable within five years. EBITDA margin expected to be in line with company average from FY2039.
Risks flagged
- Sibaji Biswas explicitly stated all Mangalore costs are routed through P&L with 100-150 bps margin dilution impact. Business development cycles in pharma manufacturing are long.
- Analyst pressed on customer pipeline and ramp-up timeline for the Stelis facility. Management deflected by emphasizing strategic rationale (3-year capacity acceleration) rather than revenue visibility. Facility currently has no committed client contracts.
- Discovery services growth has returned to more normal levels after unusually high pandemic catch-up demand last year. Private biotech funding environment remains challenging, though management characterizes this as cyclical normalization rather than structural shift.
- INR 15.5 crore forex loss vs INR 3.4 crore year-ago due to gap between hedge rate (INR 80.3) and spot rate (INR 87.2). This creates margin volatility depending on rupee movement.
Key quotes
- We have enough confidence in the demand for biologic CDMO that we've accelerated an internal growth program by 3 years by doing this.
- What we tried to indicate is we've done well enough, better than expected, over the last 18 months, two years, in our biologic CDMO business, that we're currently in danger of running out of capacity.
- The underlying base is just some really good innovation going on. On a global basis, you have aging societies and an ever-growing set of demographics that drive us to consume more healthcare.
Research modules